耳蜗基因治疗。
Cochlear Gene Therapy.
机构信息
Department of Otolaryngology-Head and Neck Surgery, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York 10032.
Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California 94117.
出版信息
Cold Spring Harb Perspect Med. 2019 Sep 3;9(9):a033191. doi: 10.1101/cshperspect.a033191.
Abstract
Over 450 million people worldwide suffer from hearing loss, leading to an estimated economic burden of ∼$750 billion. The past decade has seen significant advances in the understanding of the molecular mechanisms that contribute to hearing, and the environmental and genetic factors that can go awry and lead to hearing loss. This in turn has sparked enormous interest in developing gene therapy approaches to treat this disorder. This review documents the most recent advances in cochlear gene therapy to restore hearing loss, and will cover viral vectors and construct designs, potential routes of delivery into the inner ear, and, lastly, the most promising genes of interest.
摘要
全球有超过 4.5 亿人患有听力损失，估计造成的经济负担约为 7500 亿美元。在过去的十年中，人们对导致听力损失的分子机制以及可能出错的环境和遗传因素有了更深入的了解。这反过来又极大地激发了人们对开发基因治疗方法来治疗这种疾病的兴趣。本文回顾了耳蜗基因治疗恢复听力损失的最新进展，将涵盖病毒载体和构建设计、内耳递药的潜在途径，以及最后最有前途的感兴趣基因。
相似文献
1
Cochlear Gene Therapy.耳蜗基因治疗。
Cold Spring Harb Perspect Med. 2019 Sep 3;9(9):a033191. doi: 10.1101/cshperspect.a033191.
2
Cochlear gene therapy.耳蜗基因治疗。
Curr Opin Neurol. 2012 Feb;25(1):57-60. doi: 10.1097/WCO.0b013e32834f038c.
3
Recent advances in cochlear hair cell regeneration-A promising opportunity for the treatment of age-related hearing loss.耳蜗毛细胞再生的最新进展——治疗与年龄相关的听力损失的有希望的机会。
Ageing Res Rev. 2017 Jul;36:149-155. doi: 10.1016/j.arr.2017.04.002. Epub 2017 Apr 13.
4
New molecular therapies for the treatment of hearing loss.用于治疗听力损失的新型分子疗法。
Pharmacol Ther. 2019 Aug;200:190-209. doi: 10.1016/j.pharmthera.2019.05.003. Epub 2019 May 8.
5
Emerging Gene Therapies for Genetic Hearing Loss.针对遗传性听力损失的新兴基因疗法。
J Assoc Res Otolaryngol. 2017 Oct;18(5):649-670. doi: 10.1007/s10162-017-0634-8. Epub 2017 Aug 16.
6
Identification of Adeno-Associated Viral Vectors That Target Neonatal and Adult Mammalian Inner Ear Cell Subtypes.靶向新生和成年哺乳动物内耳细胞亚型的腺相关病毒载体的鉴定
Hum Gene Ther. 2016 Sep;27(9):687-99. doi: 10.1089/hum.2016.053. Epub 2016 Jun 24.
7
Enhanced viral-mediated cochlear gene delivery in adult mice by combining canal fenestration with round window membrane inoculation.通过结合圆窗膜接种和鼓室开窗术增强成年小鼠的病毒介导的耳蜗基因转导。
Sci Rep. 2018 Feb 14;8(1):2980. doi: 10.1038/s41598-018-21233-z.
8
Current status and prospects of gene therapy for the inner ear.内耳基因治疗的现状与展望。
Hum Gene Ther. 2011 Nov;22(11):1311-22. doi: 10.1089/hum.2010.246. Epub 2011 May 19.
9
[Gene therapy for human hearing loss: challenges and promises].[人类听力损失的基因治疗：挑战与前景]
Med Sci (Paris). 2013 Oct;29(10):883-9. doi: 10.1051/medsci/20132910016. Epub 2013 Oct 18.
10
Advances in inner ear gene therapy: exploring cochlear protection and regeneration.内耳基因治疗的进展：探索耳蜗保护与再生
Curr Opin Otolaryngol Head Neck Surg. 2005 Oct;13(5):308-12. doi: 10.1097/01.moo.0000179248.51476.11.
引用本文的文献
1
Genetic tools for studying cochlear inhibition.用于研究耳蜗抑制的遗传工具。
Front Cell Neurosci. 2024 Mar 15;18:1372948. doi: 10.3389/fncel.2024.1372948. eCollection 2024.
2
Advancements and future prospects of adeno-associated virus-mediated gene therapy for sensorineural hearing loss.腺相关病毒介导的感音神经性听力损失基因治疗的进展与未来前景
Front Neurosci. 2024 Jan 24;18:1272786. doi: 10.3389/fnins.2024.1272786. eCollection 2024.
3
Transcriptomic Analysis Identifies Candidate Genes for Differential Expression during Inner Ear Development.转录组分析确定内耳发育过程中差异表达的候选基因。
bioRxiv. 2024 Jan 1:2023.12.29.573599. doi: 10.1101/2023.12.29.573599.
4
Third-generation lentiviral gene therapy rescues function in a mouse model of Usher 1B.第三代慢病毒基因疗法可挽救1B型尤塞氏综合征小鼠模型的功能。
Mol Ther. 2023 Dec 6;31(12):3502-3519. doi: 10.1016/j.ymthe.2023.10.018. Epub 2023 Oct 31.
5
Considering gene therapy to protect from X-linked deafness DFNX2 and associated neurodevelopmental disorders.考虑采用基因疗法预防X连锁耳聋DFNX2及相关神经发育障碍。
Ibrain. 2022 Sep 27;8(4):431-441. doi: 10.1002/ibra.12068. eCollection 2022 Winter.
6
Mini-PCDH15 gene therapy rescues hearing in a mouse model of Usher syndrome type 1F.迷你 PCDH15 基因治疗挽救 1F 型 Usher 综合征小鼠模型的听力。
Nat Commun. 2023 Apr 26;14(1):2400. doi: 10.1038/s41467-023-38038-y.
7
Engineering olivocochlear inhibition to reduce acoustic trauma.通过工程手段实现橄榄耳蜗抑制以减轻声学创伤。
Mol Ther Methods Clin Dev. 2023 Feb 26;29:17-31. doi: 10.1016/j.omtm.2023.02.011. eCollection 2023 Jun 8.
8
Unlocking the human inner ear for therapeutic intervention.为治疗干预解锁人类内耳。
Sci Rep. 2022 Nov 8;12(1):18508. doi: 10.1038/s41598-022-22203-2.
9
The genetic and phenotypic landscapes of Usher syndrome: from disease mechanisms to a new classification.遗传性耳聋-视网膜色素变性综合征的遗传和表型图谱：从疾病机制到新分类
Hum Genet. 2022 Apr;141(3-4):709-735. doi: 10.1007/s00439-022-02448-7. Epub 2022 Mar 30.
10
Using Sox2 to alleviate the hallmarks of age-related hearing loss.利用 Sox2 缓解与年龄相关的听力损失的特征。
Ageing Res Rev. 2020 May;59:101042. doi: 10.1016/j.arr.2020.101042. Epub 2020 Mar 12.
本文引用的文献
1
Clarin-1 gene transfer rescues auditory synaptopathy in model of Usher syndrome.Clarin-1 基因转移可挽救乌谢尔综合征模型中的听觉突触病。
J Clin Invest. 2018 Aug 1;128(8):3382-3401. doi: 10.1172/JCI94351. Epub 2018 Jul 9.
2
Therapeutic applications of CRISPR/Cas9 system in gene therapy.CRISPR/Cas9系统在基因治疗中的治疗应用。
Biotechnol Lett. 2018 Jun;40(6):907-914. doi: 10.1007/s10529-018-2555-y. Epub 2018 Apr 28.
3
Strategies for In Vivo Genome Editing in Nondividing Cells.在非分裂细胞中进行体内基因组编辑的策略。
Trends Biotechnol. 2018 Aug;36(8):770-786. doi: 10.1016/j.tibtech.2018.03.004. Epub 2018 Apr 21.
4
Design and assessment of engineered CRISPR-Cpf1 and its use for genome editing.设计和评估工程化的 CRISPR-Cpf1 及其在基因组编辑中的应用。
Nat Protoc. 2018 May;13(5):899-914. doi: 10.1038/nprot.2018.004. Epub 2018 Apr 5.
5
Non-viral gene delivery systems for tissue repair and regeneration.非病毒基因传递系统在组织修复和再生中的应用。
J Transl Med. 2018 Feb 15;16(1):29. doi: 10.1186/s12967-018-1402-1.
6
Syndromic Hearing Loss: A Brief Review of Common Presentations and Genetics.综合征性听力损失：常见临床表现与遗传学简要综述
J Pediatr Genet. 2018 Mar;7(1):1-8. doi: 10.1055/s-0037-1617454. Epub 2018 Jan 4.
7
Emerging Issues in AAV-Mediated Gene Therapy.腺相关病毒介导的基因治疗中的新问题
Mol Ther Methods Clin Dev. 2017 Dec 1;8:87-104. doi: 10.1016/j.omtm.2017.11.007. eCollection 2018 Mar 16.
8
Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes.用于编码大转基因的腺相关病毒（AAV）双载体基因治疗策略
Yale J Biol Med. 2017 Dec 19;90(4):611-623. eCollection 2017 Dec.
9
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.体内递送基因编辑试剂治疗常染色体显性遗传性听力损失。
Nature. 2018 Jan 11;553(7687):217-221. doi: 10.1038/nature25164. Epub 2017 Dec 20.
10
Delivery of Adeno-Associated Virus Vectors in Adult Mammalian Inner-Ear Cell Subtypes Without Auditory Dysfunction.腺相关病毒载体在成年哺乳动物内耳细胞亚型中的传递，而不引起听觉功能障碍。
Hum Gene Ther. 2018 Apr;29(4):492-506. doi: 10.1089/hum.2017.120. Epub 2018 Jan 22.
Zotero 插件